Skip to main content

Table 2 Cost-effectiveness results of base-case scenario

From: Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma

Parameters

DRd group

KRd group

Increment

Cost

15,370

15,106

264

QALY

1.56

1.28

0.28

lYG

5.86

3.52

2.34

ICUR

956

ICER

472

ACER

9859

11,773

NMB

− 13,359

− 13,451

92